Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -41.09% is 62% below its 3-year average of -25.41%, near the low end of its 3-year range (-41.09%–-24.53%).
65.69% below its 12-month average of -24.80%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): -7.96%.
RETURN ON ASSETS (ROA)
-41.09%
RETURN ON ASSETS (ROA) AVG TTM
-24.80%
RETURN ON ASSETS (ROA) AVG 3Y
-25.41%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-65.69%
CURRENT VS 3Y AVG
-61.69%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.81%
median of 841 covered companies
CURRENT VS SECTOR MEDIAN
-29.17%
vs the sector median at left
Citius Oncology, Inc.
Market Cap
$80.88M
Return on Assets (ROA)
-41.09%
TTM Avg
-24.80%
3Y Avg
-25.41%
5Y Avg
N/A
Market Cap
$80.47M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
Market Cap
$80.11M
Return on Assets (ROA)
-110.64%
TTM Avg
-124.68%
3Y Avg
-93.30%
5Y Avg
-78.61%
Market Cap
$81.70M
Return on Assets (ROA)
-107.29%
TTM Avg
-60.42%
3Y Avg
-51.23%
5Y Avg
-39.69%
Market Cap
$82.05M
Return on Assets (ROA)
-74.48%
TTM Avg
-208.94%
3Y Avg
-35981.57%
5Y Avg
-24064.76%
Market Cap
$82.20M
Return on Assets (ROA)
-26.59%
TTM Avg
-23.05%
3Y Avg
-19.50%
5Y Avg
-17.99%
Market Cap
$82.37M
Return on Assets (ROA)
-70.05%
TTM Avg
-71.47%
3Y Avg
-58.80%
5Y Avg
-51.13%
Market Cap
$83.22M
Return on Assets (ROA)
-109.51%
TTM Avg
-695.26%
3Y Avg
-854.30%
5Y Avg
-733.67%
Market Cap
$83.51M
Return on Assets (ROA)
49.88%
TTM Avg
-47.68%
3Y Avg
-37.92%
5Y Avg
-34.36%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | $80.88M | -41.09% | -24.80% | -25.41% | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.47M | -74.91% | -50.52% | -40.48% | -70.00% |
| Nutriband Inc. (NTRB)vs › | $80.11M | -110.64% | -124.68% | -93.30% | -78.61% |
| Cardiff Oncology, Inc. (CRDF)vs › | $81.70M | -107.29% | -60.42% | -51.23% | -39.69% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.05M | -74.48% | -208.94% | -35981.57% | -24064.76% |
| MediciNova, Inc. (MNOV)vs › | $82.20M | -26.59% | -23.05% | -19.50% | -17.99% |
| Humacyte, Inc. (HUMA)vs › | $82.37M | -70.05% | -71.47% | -58.80% | -51.13% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $83.22M | -109.51% | -695.26% | -854.30% | -733.67% |
| LENSAR Inc (LNSR)vs › | $83.51M | 49.88% | -47.68% | -37.92% | -34.36% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | -136.52% | -104.53% | -92.09% | -76.74% |
ROA
-41.1%
ROE
-114.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -24.53% |
| 2024-09-30 | -25.07% |
| 2023-09-30 | -26.60% |
| 2022-09-30 | -25.45% |
